Next-generation sequencing offers new insights into the resistance of Candida spp. To echinocandins and azoles

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2556-2565

  Garnaud, Cécile ^a,b   Botterel, Françoise ^c,d   Sertour, Natacha ^e   Bougnoux, Marie Elisabeth ^e,f   Dannaoui, Eric ^d,g   Larrat, Sylvie ^a,b   Hennequin, Christophe ^h,i   Guinea, Jesus ^j   Cornet, Muriel ^a,b   Maubon, Danièle ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^e INSTITUT PASTEUR   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

Antifungals; Mutations; NGS

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; PYRROLE DERIVATIVE; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CGPDR1 GENE; CODING; ERG11 GENE; ERG3 GENE; FKS1 GENE; FKS2 GENE; FUNGAL GENE; FUNGUS MUTATION; GAIN OF FUNCTION MUTATION; GENOME ANALYSIS; LOSS OF FUNCTION MUTATION; NEXT GENERATION SEQUENCING; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TAC1 GENE; CANDIDIASIS; DRUG EFFECTS; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MUTATION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION;

EID: 84954285526     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv139     Document Type: Article

References (34)

1. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724-32.
2. Shields RK, Nguyen MH, Press EG et al. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013; 57: 3528-35.
3. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
4. Cannon RD, Lamping E, Holmes AR et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 2009; 22: 291-321.
5. Sanglard D, Coste A, Ferrari S. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 2009; 9: 1029-50.
6. Morio F, Loge C, Besse B et al. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: newsubstitutions and a review of the literature. Diagn Microbiol Infect Dis 2010; 66: 373-84.
7. Morio F, Pagniez F, Lacroix C et al. Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J Antimicrob Chemother 2012; 67: 2131-8.
8. Shields RK, Nguyen MH, Press EG et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 2012; 56: 4862-9.
9. Pfaller MA, Castanheira M, Lockhart SR et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-203.
10. Pham CD, Iqbal N, Bolden CB et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58: 4690-6.
11. Hauser PM, Bernard T, Greub G et al. Microbiota present in cystic fibrosis lungs as revealed by whole genome sequencing. PLoS One 2014; 9: e90934.
12. Delhaes L, Monchy S, Fréalle E et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS One 2012; 7: e36313.
13. Angebault C, Djossou F, Abélanet S et al. Candida albicans is not always the preferential yeast colonizing humans: a study in Wayampi Amerindians. J Infect Dis 2013; 208: 1705-16.
14. Rodriguez-Tudela JL, Arendrup MC, Barchiesi F et al. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Clin Microbiol Infect 2008; 14: 398-405.
15. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C et al. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013; 16: 81-95.
16. Bougnoux M-E, Tavanti A, Bouchier C et al. Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol 2003; 41: 5265-6.
17. Sabino R, Sampaio P, Rosado L et al. New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol 2010; 48: 1677-82.
18. Enache-Angoulvant A, Bourget M, Brisse S et al. Multilocus microsatellite markers for molecular typing of Candida glabrata: application to analysis of genetic relationships between bloodstream and digestive system isolates. J Clin Microbiol 2010; 48: 4028-34.
19. Perea S, López-Ribot JL, Kirkpatrick WR et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-84.
20. Chau AS, Gurnani M, Hawkinson R et al. Inactivation of sterol D5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother 2005; 49: 3646-51.
21. Kolaczkowska A, Kolaczkowski M, Delahodde A et al. Functional dissection of Pdr1p, a regulator of multidrug resistance in Saccharomyces cerevisiae. Mol Genet Genomics 2002; 267: 96-106.
22. Vermitsky J-P, Earhart KD, Smith WL et al. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol Microbiol 2006; 61: 704-22.
23. Schwarzmüller T, Ma B, Hiller E et al. Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes. PLoS Pathog 2014; 10: e1004211.
24. Thakur JK, Arthanari H, Yang F et al. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452: 604-9.
25. Singh-Babak SD, Babak T, Diezmann S et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog 2012; 8: e1002718.
26. Ferrari S, Ischer F, Calabrese D et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog 2009; 5: e1000268.
27. Garcia-Effron G, Lee S, Park S et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53: 3690-9.
28. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18: 86-90.
29. Sanguinetti M, Posteraro B, Fiori B et al. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005; 49: 668-79.
30. Silva AP, Miranda IM, Guida A et al. Transcriptional profiling of azoleresistant Candida parapsilosis strains. Antimicrob Agents Chemother 2011; 55: 3546-56.
31. Chapeland-Leclerc F, Hennequin C, Papon N et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54: 1360-2.
32. Coste AT, Karababa M, Ischer F et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639-52.
33. Sanglard D, Kuchler K, Ischer F et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86.
34. MacCallum DM, Coste A, Ischer F et al. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. Antimicrob Agents Chemother 2010; 54: 1476-83.